Abstract
Shire has moved to strengthen its haematology franchise by agreeing to acquire FerroKin BioSciences for up to US$325 M. With the acquisition, Shire will gain FerroKin’s iron chelator FBS0701, which is in Phase II development for the treatment of iron overload due to chronic blood transfusions. Shire will pay US$100 M upfront in cash and up to US$225 M in potential clinical development, regulatory and commercial milestones related to the drug, which could be launched as early as 2016.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
